Generic Name:
lisdexamfetamine dimesylate

Trade Name:
Vyvanse ® [Shire]

IUPAC Name:
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-
2-yl]hexanamide; methanesulfonic acid

Dosage Forms/Routes:
Capsule/oral

Major Metabolites:
p-hydroxyamphetamine;
p-hydroxynorephedrine

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
02/23/2007


Manufacturers:

[FDA Search]

Product Insert:
[Link]

RxList:
[Link]

Epocrates:
[Link]

Empirical Formula:
C17H33N3O7S2

Molecular Mass:
455.58982 g/mol

Indications:
ADHD
Possible Mechanisms of Action:
Vyvanse is a prodrug of dextroamphetamine. After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug's activity.

Chemical Class:
prodrug of the dextro isomer of d,l-amphetamine sulfate

PubChem 2D Structure: